IXICO (LON:IXI) Stock Price Crosses Above 50-Day Moving Average – Time to Sell?

IXICO plc (LON:IXI) passed above its fifty day moving average during trading on Monday . The stock has a fifty day moving average of GBX 11.79 ($0.15) and traded as high as GBX 11.89 ($0.15). IXICO shares last traded at GBX 11.89 ($0.15), with a volume of 8 shares traded.

IXICO Trading Down 2.0 %

The firm has a market capitalization of £5.57 million, a PE ratio of -287.75, a price-to-earnings-growth ratio of -0.38 and a beta of 0.86. The company has a debt-to-equity ratio of 3.22, a current ratio of 3.64 and a quick ratio of 4.90. The company has a fifty day moving average of GBX 11.79 and a 200-day moving average of GBX 10.11.

IXICO (LON:IXI) last posted its quarterly earnings results on Wednesday, December 4th. The company reported GBX (4.14) (($0.05)) earnings per share for the quarter. IXICO had a negative return on equity of 16.99% and a negative net margin of 31.10%. On average, sell-side analysts anticipate that IXICO plc will post -289.3584879 earnings per share for the current fiscal year.

Insider Buying and Selling at IXICO

In related news, insider Grant Nash bought 260,000 shares of the business’s stock in a transaction on Wednesday, December 4th. The shares were bought at an average cost of GBX 12 ($0.15) per share, for a total transaction of £31,200 ($38,556.60). Corporate insiders own 30.28% of the company’s stock.

IXICO Company Profile

IXICO is a fast growing and profitable medical data analytics company, providing data management and advanced analytics to the pharmaceutical clinical trials market. Established in 2004 and listed as a public company in October 2013, IXICO has firmly established itself as a trusted partner to the global pharmaceutical industry developing new therapies for neurological conditions such as Alzheimer’s, Parkinson’s and Huntington’s disease.

Our purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience.